Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) - Equities researchers at Zacks Research lifted their Q2 2027 earnings estimates for Amicus Therapeutics in a note issued to investors on Wednesday, July 9th. Zacks Research analyst R. Department now anticipates that the biopharmaceutical company will earn $0.10 per share for the quarter, up from their previous estimate of $0.09. The consensus estimate for Amicus Therapeutics' current full-year earnings is $0.15 per share.
A number of other research firms also recently commented on FOLD. UBS Group raised their target price on shares of Amicus Therapeutics from $21.00 to $22.00 and gave the company a "buy" rating in a research report on Friday, May 2nd. Wall Street Zen downgraded shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a research report on Monday, May 5th. Finally, The Goldman Sachs Group cut their price objective on shares of Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating on the stock in a research report on Friday, May 2nd. Four equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $16.22.
Read Our Latest Report on Amicus Therapeutics
Amicus Therapeutics Trading Down 1.9%
FOLD stock opened at $6.30 on Friday. The company has a market capitalization of $1.94 billion, a PE ratio of -69.99 and a beta of 0.51. Amicus Therapeutics has a 12 month low of $5.51 and a 12 month high of $12.65. The firm's 50-day moving average is $6.09 and its 200 day moving average is $7.81. The company has a debt-to-equity ratio of 2.02, a current ratio of 3.34 and a quick ratio of 2.47.
Institutional Trading of Amicus Therapeutics
Several institutional investors and hedge funds have recently bought and sold shares of the business. Raymond James Financial Inc. acquired a new position in shares of Amicus Therapeutics in the 4th quarter valued at $132,000. AlphaQuest LLC lifted its stake in shares of Amicus Therapeutics by 635.1% in the 4th quarter. AlphaQuest LLC now owns 10,732 shares of the biopharmaceutical company's stock valued at $101,000 after purchasing an additional 9,272 shares during the period. Connor Clark & Lunn Investment Management Ltd. lifted its stake in shares of Amicus Therapeutics by 35.7% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 302,536 shares of the biopharmaceutical company's stock valued at $2,850,000 after purchasing an additional 79,602 shares during the period. Swiss National Bank lifted its stake in shares of Amicus Therapeutics by 0.7% in the 4th quarter. Swiss National Bank now owns 437,500 shares of the biopharmaceutical company's stock valued at $4,121,000 after purchasing an additional 3,200 shares during the period. Finally, Cibc World Markets Corp acquired a new position in shares of Amicus Therapeutics in the 4th quarter valued at $259,000.
About Amicus Therapeutics
(
Get Free Report)
Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Amicus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amicus Therapeutics wasn't on the list.
While Amicus Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.